Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Diabetes

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIABETES.54.1.146PMID 15616022
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GLP-1 inhibition of pancreatic islet cell apoptosis.

  2004influential reference
• New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.

  2004influential reference
• Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.

  2004influential reference
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

  2004influential reference
• cAMP Dose-dependently Prevents Palmitate-induced Apoptosis by Both Protein Kinase A- and cAMP-Guanine Nucleotide Exchange Factor-dependent Pathways in β-Cells*

  2004cited by this paper
• Cyclic AMP dose-dependently prevents palmitate-induced apoptosis by both PKA-and cAMP-GEF-dependent pathways in b -Cells.

  2003cited by this paper
• Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2

  2003cited by this paper
• PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

  2003influential reference
• Cardiac function in mice lacking the glucagon-like peptide-1 receptor.

  2003influential reference
• Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway.

  2003cited by this paper
• Cell signalling of the GLP-1 action in rat liver.

  2003cited by this paper
• Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.

  2003influential reference
• Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis*

  2003cited by this paper
• Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

  2002influential reference
• Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.

  2002influential reference
• PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning.

  2002influential reference
• Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.

  2002influential reference
• Metabolic modulation of acute myocardial infarction.

  2001cited by this paper
• When is cAMP not cAMP? Effects of compartmentalization.

  2001cited by this paper
• Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes

  2001influential reference
• Insulin treatment post myocardial infarction: the DIGAMI study.

  2001cited by this paper
• Myocardial Protection by Insulin at Reperfusion Requires Early Administration and Is Mediated via Akt and p70s6 Kinase Cell-Survival Signaling

  2001influential reference
• Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.

  2001influential reference
• Ischemic Preconditioning Activates Phosphatidylinositol-3-Kinase Upstream of Protein Kinase C

  2000influential reference
• Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism.

  2000influential reference
• Myocardial protection by insulin is dependent on phospatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart

  1999influential reference
• Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats.

  1999influential reference
• Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats.

  1999cited by this paper
• Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

  1999influential reference
• Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial

  1998cited by this paper
• Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group.

  1998cited by this paper
• Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

  1998cited by this paper
• Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig.

  1996influential reference
• Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.

  1996influential reference
• Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

  1996influential reference
• Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences

  1995cited by this paper
• Activation of a cAMP-regulated Ca-Signaling Pathway in Pancreatic -Cells by the Insulinotropic Hormone Glucagon-like Peptide-1 (*)

  1995cited by this paper
• Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.

  1994cited by this paper
• Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.

  1992influential reference

• Myocardial ischemia reperfusion in diabetes: mechanism of injury and its drug treatment

  2026cites this paper
• Targeting GLP1 receptor for reducing global cardiovascular risk.

  2026cites this paper
• A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.

  2026cites this paper
• Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity

  2026cites this paper
• GLP-1 activates KATP channels in coronary pericytes as the effector of brain-gut-heart signalling mediating cardioprotection.

  2026cites this paper
• Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis

  2025cites this paper
• Role of GLP-1 receptor agonists in sepsis and their therapeutic potential in sepsis-induced muscle atrophy (Review)

  2025cites this paper
• Enteral Lactoferrin Mitigates Myocardial ischemia-reperfusion Injury Via Enteral Lactoferrin-induced glucagon-like peptide-1 in Isolated Rat Heart Model

  2025cites this paper
• Peptides are cardioprotective drugs of the future. Glucagon-like peptide-1

  2025cites this paper
• Cardioprotection During Myocardial Infarction in Diabetic Cardiomyopathy

  2025cites this paper
• Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight

  2025cites this paper
• New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions

  2024cites this paper
• Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review

  2024cites this paper
• The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease

  2024cites this paper
• Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart

  2024cites this paper
• GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms

  2024cites this paper
• Gut Hormones in Heart Failure.

  2024cites this paper
• Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists

  2024influential citation
• The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties

  2024cites this paper
• Liraglutide Protects Pancreatic Islet From Ischemic Injury by Reducing Oxidative Stress and Activating Akt Signaling During Cold Preservation to Improve Islet Transplantation Outcomes

  2024cites this paper
• Nanodomain cAMP signalling in cardiac pathophysiology: potential for developing targeted therapeutic interventions.

  2024cites this paper
• Contractile Effects of Semaglutide in the Human Atrium

  2024cites this paper
• Protective effects of sitagliptin on methotrexate-induced nephrotoxicity in rats

  2023cites this paper
• The Role of P53 in Myocardial Ischemia-Reperfusion Injury

  2023cites this paper
• Potential Role of GLP-1 Based Therapeutics in Coronary Artery Disease.

  2023cites this paper
• Thalidomide and a Dipeptidyl Peptidase 4 Inhibitor in a Rat Model of Experimental Autoimmune Myocarditis

  2023cites this paper
• Biology and Clinical Use of Glucagon-Like-Peptide-1 Receptor Agonists in Vascular Protection.

  2023cites this paper
• Role of GLP-1 receptor agonist in diabetic cardio-renal disorder: Recent updates of clinical and pre-clinical evidence.

  2023cites this paper
• Liraglutide Accelerates Ischemia-Induced Angiogenesis in a Murine Diabetic Model.

  2023cites this paper
• Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

  2023cites this paper
• Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis

  2022cites this paper
• Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction

  2022cites this paper
• The potential of glucagon-like peptide-1 receptor agonists in heart failure

  2022cites this paper
• How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma

  2022cites this paper
• Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning

  2022cites this paper
• Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury

  2022cites this paper
• Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art

  2022cites this paper
• Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension

  2022cites this paper
• A comparative study of the cardioprotective effect of Metformin, Sitagliptin and Dapagliflozin on Isoprenaline induced myocardial infarction in non-diabetic rats

  2022cites this paper
• Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials

  2022cites this paper
• New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease

  2022cites this paper
• Physiological And Pathological Roles Of Protein Kinase A In The Heart.

  2021influential citation
• Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

  2021cites this paper
• Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity

  2021cites this paper
• Cardiovascular protective effects of GLP-1:A focus on the MAPK signaling pathway.

  2021cites this paper
• Cardiac cAMP-PKA Signaling Compartmentalization in Myocardial Infarction

  2021cites this paper
• Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus

  2021cites this paper
• Effect of sleeve gastrectomy, Roux-en-Y gastric bypass, and ileal transposition on myocardial ischaemia–reperfusion injury in non-obese non-diabetic rats

  2021cites this paper
• Identification of a novel native peptide derived from 60S ribosomal protein L23a that translationally regulates p53 to reduce myocardial ischemia-reperfusion.

  2021cites this paper
• Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift.

  2021cites this paper
• Hypothalamic GPCR Signaling Pathways in Cardiometabolic Control

  2021cites this paper
• Stress Induced Hyperglycemia in the Context of Acute Coronary Syndrome: Definitions, Interventions, and Underlying Mechanisms

  2021cites this paper
• POTENTIAL ROLE OF GLP-1 RECEPTOR AGONIST IN A RAT MODEL OF CARDIO-RENAL SYNDROME TYPE-3: EFFECTS ON OXIDATIVE, INFLAMMATORY AND INOS EXPRESSION AXIS

  2021cites this paper
• Exendin-4 inhibits high glucose-induced oxidative stress in retinal pigment epithelial cells by modulating the expression and activation of p66Shc

  2021cites this paper
• Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor

  2021cites this paper
• CHARACTERIZING NOVEL GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES FOR NUCLEAR IMAGING OF THE PANCREATIC BETA CELLS

  2021cites this paper
• A Glucagon-like Peptide 1 Analog Protects Mitochondria and Attenuates Hypoxia–Reoxygenation Injury in Cultured Cardiomyocytes

  2021cites this paper
• Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation

  2021influential citation
• Incretins in the Therapy of Diabetic Kidney Disease

  2021cites this paper
• Role of glucagon-like peptide-1 agonist in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: A meta-analysis

  2021cites this paper
• Does Weight Loss Improve Clinical Outcomes in Overweight and Obese Patients with Heart Failure?

  2020cites this paper
• Pre- and post-conditioning of the heart: an overview of cardioprotective signaling pathways.

  2020cites this paper
• Oxidation of Protein Kinase A Regulatory Subunit PKARIα Protects Against Myocardial Ischemia-Reperfusion Injury by Inhibiting Lysosomal-Triggered Calcium Release

  2020cites this paper
• Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection

  2020cites this paper
• Notch signaling is involved in the antiapoptotic effects of liraglutide on rat H9c2 cardiomyocytes exposed to hypoxia followed by reoxygenation

  2020cites this paper
• Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study

  2020cites this paper
• The vicious circle of left ventricular dysfunction and diabetes: from pathophysiology to emerging treatments.

  2020cites this paper
• GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients.

  2020cites this paper
• Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

  2020cites this paper
• SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention.

  2020cites this paper
• Kaempferol Regulates miR-15b/Bcl-2/TLR4 to Alleviate OGD-Induced Injury in H9c2 Cells.

  2020cites this paper
• Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α.

  2020cites this paper
• Diabetic cardiomyopathy.

  2020cites this paper
• GLP‐1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes

  2020cites this paper
• Treatment of Obesity in Mitigating Metabolic Risk.

  2020cites this paper
• Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis

  2020cites this paper
• Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2.

  2020cites this paper
• Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions.

  2020cites this paper
• Liraglutide ameliorates COCl2-induced oxidative stress and apoptosis in H9C2 cells via regulating cell autophagy

  2020cites this paper
• Diabetic cardiomyopathy.

  2020cites this paper
• Protective effect of exenatide (glucagon-like peptide-1 receptor agonist) on renal ischemia–reperfusion injury in diabetic rats

  2020cites this paper
• The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs.

  2020cites this paper
• Glucagon-Like Peptide-1–Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion

  2019cites this paper
• Remote ischemic conditioning to protect the heart in myocardial infarction : therapeutic intervention and underlying mechanisms

  2019cites this paper
• Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials

  2019cites this paper
• An investigation into the role of the CXCR7 Chemokine receptor in acute myocardial infarction and angiogenesis

  2019cites this paper
• Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.

  2019cites this paper
• Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection

  2019cites this paper
• Glucagon-like peptide-1 attenuates endoplasmic reticulum stress–induced apoptosis in H9c2 cardiomyocytes during hypoxia/reoxygenation through the GLP-1R/PI3K/Akt pathways

  2019cites this paper
• Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide

  2019cites this paper
• Antihyperglycemic drugs that improve cardiovascular outcomes and a model of diabetic cardiomyopathy

  2019cites this paper
• Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review.

  2019cites this paper
• The Intestine Responds to Heart Failure by Enhanced Mitochondrial Fusion through Glucagon-like Peptide-1 Signaling.

  2019cites this paper
• Exenatide alleviates adriamycin-induced heart dysfunction in mice: Modulation of oxidative stress, apoptosis and inflammation.

  2019cites this paper
• Exenatide reduces cardiomyocyte apoptosis by stimulating adiponectin secretion and activating APPL1-AMPK-PPARα axis.

  2019cites this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cites this paper
• Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

  2019cites this paper
• Preliminary evaluation of 18F-AlF-NOTA-MAL-Cys40-Exendin-4 in rodent heart after myocardial ischemia and reperfusion

  2019cites this paper
• The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial.

  2019cites this paper
• Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model

  2019cites this paper